Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SHE: 002603)

Shijiazhuang Yiling Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	8,106	10,315	12,520	10,111	8,774	5,803
Other Revenue	3.48	3.48	13.04	6.12	8.42	22.67
Revenue	8,109	10,318	12,533	10,117	8,782	5,825
Revenue Growth (YoY)	-38.39%	-17.67%	23.88%	15.19%	50.76%	20.99%
Cost of Revenue	4,058	4,434	4,556	3,700	3,125	2,106
Gross Profit	4,051	5,884	7,976	6,417	5,658	3,719
Selling, General & Admin	2,843	3,297	3,871	3,931	3,436	2,579
Research & Development	831.39	853.19	1,032	792.16	654.39	390.75
Other Operating Expenses	196.24	99.27	203.45	138.41	136.29	93.97
Operating Expenses	3,900	4,271	5,123	4,898	4,231	3,068
Operating Income	150.91	1,613	2,853	1,519	1,426	650.84
Interest Expense	-41.49	-38.9	-33.8	-33.97	-10.96	-0.07
Interest & Investment Income	30.99	42.04	12.9	20.45	38.51	35.57
Currency Exchange Gain (Loss)	-0.21	-0.21	4.16	-1.25	0.02	0.04
Other Non Operating Income (Expenses)	15.73	-4.83	-49.4	-3.31	-16.57	-9.21
EBT Excluding Unusual Items	155.93	1,611	2,787	1,501	1,437	677.17
Impairment of Goodwill	-0.52	-0.52	-	-	-	-
Gain (Loss) on Sale of Investments	34.18	39.35	11.5	-21.9	5.23	2.04
Gain (Loss) on Sale of Assets	-1.1	-0.82	-3.11	-3.37	0.14	-0.24
Asset Writedown	0.61	-10.63	-95.62	-9.91	-53.12	-1.25
Other Unusual Items	61.13	45.88	80.56	88.23	32.87	30.16
Pretax Income	250.23	1,684	2,781	1,554	1,422	707.89
Income Tax Expense	110.78	339.91	422.87	212.09	207.54	104.84
Earnings From Continuing Operations	139.45	1,344	2,358	1,342	1,215	603.04
Minority Interest in Earnings	9.02	8.08	4.98	2.22	3.81	3.46
Net Income	148.47	1,352	2,363	1,344	1,219	606.5
Net Income to Common	148.47	1,352	2,363	1,344	1,219	606.5
Net Income Growth	-94.52%	-42.76%	75.82%	10.27%	100.95%	1.21%
Shares Outstanding (Basic)	1,671	1,671	1,671	1,671	1,671	1,665
Shares Outstanding (Diluted)	1,671	1,671	1,671	1,671	1,671	1,665
Shares Change (YoY)	-0.01%	-0.01%	0.01%	-0.00%	0.35%	-0.79%
EPS (Basic)	0.09	0.81	1.41	0.80	0.73	0.36
EPS (Diluted)	0.09	0.81	1.41	0.80	0.73	0.36
EPS Growth	-94.52%	-42.76%	75.81%	10.27%	100.25%	2.02%
Free Cash Flow	-2.96	-155.38	3,274	-144.87	441.39	-385.5
Free Cash Flow Per Share	-0.00	-0.09	1.96	-0.09	0.26	-0.23
Dividend Per Share	0.300	0.300	0.500	0.300	0.714	0.143
Dividend Growth	-40.00%	-40.00%	66.67%	-58.00%	399.86%	100.14%
Gross Margin	49.96%	57.03%	63.64%	63.43%	64.42%	63.84%
Operating Margin	1.86%	15.63%	22.77%	15.01%	16.24%	11.17%
Profit Margin	1.83%	13.11%	18.85%	13.28%	13.88%	10.41%
Free Cash Flow Margin	-0.04%	-1.51%	26.12%	-1.43%	5.03%	-6.62%
EBITDA	764.15	2,152	3,294	1,871	1,695	910.53
EBITDA Margin	9.42%	20.86%	26.28%	18.50%	19.29%	15.63%
D&A For EBITDA	613.24	539.25	440.6	352.61	268.16	259.69
EBIT	150.91	1,613	2,853	1,519	1,426	650.84
EBIT Margin	1.86%	15.63%	22.77%	15.01%	16.24%	11.17%
Effective Tax Rate	44.27%	20.18%	15.21%	13.65%	14.59%	14.81%
Revenue as Reported	8,109	10,318	12,533	10,117	8,782	5,825

Source: S&P Capital IQ. Standard template. Financial Sources.